A 10-Year Community-Based Study of Leucine-Rich Repeat Kinase 2 G2385R Carriers' Conversion to Parkinson's Disease
A 10-Year Community-Based Study of Leucine-Rich Repeat Kinase 2 G2385R Carriers' Conversion to Parkinson's Disease
复制标题
针对富含亮氨酸重复激酶 2 G2385R 携带者转化为帕金森病的为期 10 年的社区研究
DOI:
10.1002/mds.29127
复制
发表时间:
2022-06-22
影响因子:
8.6
通讯作者:
Ma,Jianfang
中科院分区:
文献类型:
--
作者:
Wang,Pei;Pan,Jing;Ma,Jianfang
BackgroundThe G2385R variant of leucine‐rich repeat kinase 2 (LRRK2) is mainly associated with Parkinson's disease(PD) in Asian populations.ObjectiveThe aim of this study was to investigate the PD conversion rate and clinical characteristics of LRRK2 G2385R nonmanifesting carriers.MethodsAll participants were from the community‐based longitudinal cohort of Shanghai Ruijin Hospital. The G2385R carriers and noncarriers were screened by Sanger sequencing and received face‐to‐face interviews at baseline and follow‐up assessments. The Kaplan–Meier method was used to compare the conversion rate of PD. Cox regression models were used to estimate the risk of G2385R variant for PD.ResultsIn the combined cohort, 26 (7.9%) people developed PD in 329 carriers versus 9 (2.6%) in 345 noncarriers (P= 0.0016). Cox regression model confirmed that the G2385R variant was a strong risk factor for PD in a Chinese population older than 50 years (hazard ratio, 3.314; 95% confidence interval, 1.551–7.078;P= 0.002). No difference was found in clinical symptoms between carriers and noncarriers.ConclusionsWe confirmed an increased conversion of PD in leucine‐rich repeat kinase 2 G2385R carriers during a 10‐year follow‐up. © 2022 International Parkinson and Movement Disorder Society.